Posted by Michael Wonder on 12 May 2020
ZolpiMist update
12 May 2020 - SUDA submitted a marketing authorisation application to the TGA for ZolpiMist in April 2019.
SUDA, subsequent to the submission, made a strategic decision to register a supplemental active pharmaceutical ingredient (API) supplier and manufacturer which required an amendment to the TGA submission.
The outcome of the strategic decision is a reduction of the costs of raw material and finished product which will enable SUDA to create additional value over the medium to long-term from its existing partnerships and to establish additional partnerships across more territories.
